NeuroMetrix Reports Q3 2024 Business Highlights
05 nov. 2024 07h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine months ended September 30, 2024. The...
NeuroMetrix Reiterates its Review of Strategic Alternatives
13 août 2024 14h47 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strategic alternatives. In...
NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options
06 août 2024 07h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix, Inc. today reported financial and business highlights for the quarter and six months ended June 30, 2024.
NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call
31 juil. 2024 14h03 HE
|
NeuroMetrix, Inc.
NeuroMetrix plans to issue its 2024 second quarter business and financial highlights before the opening of the market on August 6, 2024.
NeuroMetrix Reports Q1 2024 Business Highlights
15 mai 2024 16h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix, Inc. today reported financial and business highlights for the quarter ended March 31, 2024.
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
19 avr. 2024 08h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix today announced two steps to enhance shareholder value following feedback and recommendations from one of its largest shareholders.
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
14 mars 2024 09h00 HE
|
NeuroMetrix, Inc.
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck® combined with standard EKG or DPNCheck...
NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia
13 mars 2024 09h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia since its strategic commercial launch in Dec 2022.
NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
22 févr. 2024 07h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix, Inc. today reported financial and business highlights for the quarter and full year ended December 31, 2023.
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call
15 févr. 2024 09h00 HE
|
NeuroMetrix, Inc.
NeuroMetrix plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.